Omid Hamid on Vigilance with Toxicities from Combination Immunotherapies
Dr. Omid Hamid discusses some toxicities that come from combination immunotherapies
Omid Hamid, MD, chief of Translational Research and Immunotherapy of The Angeles Clinic, discusses some toxicities that come from combination immunotherapies, such as type 1 diabetes and hypoadrenalism.
Despite the ease with which these adverse events can usually be remedied, Hamid urges clinicians to carefully consider a patient’s complaints. If these toxicities are caught early enough, they are less complicated to deal with.
Stopping ICIs at 1 or 2 Years May Not Compromise Survival in HNSCC
September 11th 2024This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
